Patents Examined by Samantha L Shterengarts
  • Patent number: 11981664
    Abstract: The invention relates to the field of medicine and medicinal chemistry, more in particular to the design, manufacture and use of anti-cancer drugs that can be activated by an external stimulus that can be applied in a spatiotemporal fashion. Provided herein is a compound having the chemical structure or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: May 14, 2024
    Assignees: Rijksuniversiteit Groningen, Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
    Inventors: Mickel Jens Hansen, Bernard Lucas Feringa, Femke Maria Feringa
  • Patent number: 11981665
    Abstract: The invention provide novel pyrimidine derivatives and analogs having inhibitory activities towards certain tyrosine kinases, e.g., Bruton's tyrosine kinase (Btk) and/or Focal adhesion kinase (FAK), extracellular signal-regulated kinase (ERK), pharmaceutical compositions thereof, and methods of treatment, reduction or prevention of certain diseases or conditions mediated by such by tyrosine kinases, e.g., cancers, tumors, fibrosis, inflammatory diseases, autoimmune diseases, diabetes, or immunologically mediated diseases.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: May 14, 2024
    Inventor: Zhihong Chen
  • Patent number: 11981667
    Abstract: The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: August 16, 2022
    Date of Patent: May 14, 2024
    Assignee: INFLAZOME LIMITED
    Inventors: Matthew Cooper, David Miller, Angus MacLeod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
  • Patent number: 11975030
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of lung disease, including at least chronic obstructive pulmonary disease (COPD). In particular cases, fibroblasts (including activated fibroblasts) and/or exosomes thereof are provided to an individual for the treatment of COPD. In particular cases the fibroblasts are activated and/or express one or more particular markers.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: May 7, 2024
    Assignee: Figene, LLC
    Inventors: Pete O'Heeron, Thomas Ichim
  • Patent number: 11976081
    Abstract: An intermediate compound is prepared and used for the synthesis of halichondrin B, eribulin or an analog thereof, particularly a structural fragment C27-C35 thereof. The starting materials of the synthetic route are readily available, and the optical purity of the starting materials can be ensured, so that the optical purity of the structural fragment C27-C35 in halichondrin B, eribulin or the analog thereof is ensured. Steps for constructing a chiral center of the structural fragment C27-C35 feature higher diastereoselectivity and yield, in particular preparation methods of compounds of formulae (X), (XI), (XVI) and (XV). By-products of partial reactions can be removed only by recrystallization, which results in easy purification and significant reduce in cost.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: May 7, 2024
    Assignee: BEIJING TIENYI LUFU PHARMATECH CO. LTD.
    Inventor: Weiping Xu
  • Patent number: 11976054
    Abstract: The present invention relates to an amide derivative and use thereof in medicine, and specifically to an amide derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, deuteride, prodrug, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition containing the same, and use of the compound or the composition disclosed herein in preparing an NLRP3 inhibitor.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: May 7, 2024
    Assignee: Chengdu Baiyu Pharmaceutical Co., Ltd.
    Inventors: Yonggang Wei, Hongzhu Chu, Yue Gao, Lingfeng Xiong, Guizhuan Su, Meiwei Wang, Yi Sun
  • Patent number: 11970440
    Abstract: An 8-(3-chlorobenzylideneamino)naphthalene-1,3-disulfonic acid compound, its synthesis, and its use as an antioxidant agent.
    Type: Grant
    Filed: October 30, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11970475
    Abstract: A 4-(1-(2-Hydroxypropyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-3-ol compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: September 5, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Adel A. Marzouk
  • Patent number: 11964977
    Abstract: This invention provides for compounds of the formula: wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation or infection in an animal in need thereof by administering an effective amount of these compounds to said animal.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: April 23, 2024
    Assignee: Boehringer Ingelheim Animal Health USA Inc.
    Inventors: Hannes Fiepko Koolman, Bart Herlé, Alan Long
  • Patent number: 11964985
    Abstract: The invention provides methods of inhibiting the growth or metastasis of a cancer in a mammal by inhibiting a Ral GTPase in the mammal. The invention also provides small molecule inhibitors of Ral GTPases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds of the invention, and methods of using the same.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: April 23, 2024
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Dan Theodorescu, Michael Fitzpatrick Wempe, David Ross, Samy Meroueh, Martin A. Schwartz, Phillip Reigan
  • Patent number: 11957763
    Abstract: The invention relates to a novel linker for use in bioconjugates such as antibody-drug-conjugates. The linker according to the invention is represented by formula: wherein: BM is a branching moiety; E is a capping group; SG is a sulfamide group; b, c, d, e, g, i, k, l are independently 0 or 1; f is an integer in the range of 1 to 10; Sp1, Sp2, Sp3, Sp4, Sp5 and Sp6 are a spacer moieties; Z1 and Z2 are connecting groups. The linker according to the invention is useful in the preparation of linker-conjugates and bioconjugates, and can be used for (a) improving conjugation efficiency in the preparation of the bioconjugate, (b) reducing aggregation during the preparation of the bioconjugate and/or of the bioconjugate, (c) increasing stability of the bioconjugate, and/or (d) increasing therapeutic index of the bioconjugate.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: April 16, 2024
    Assignee: SYNAFFIX B.V.
    Inventors: Sander Sebastiaan Van Berkel, Ryan Heesbeen, Jorge Merijn Mathieu Verkade, Maria Antonia Wijdeven, Floris Louis Van Delft
  • Patent number: 11958830
    Abstract: The disclosure provides at compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating a disease and/or a symptom of a disease caused by a coronavirus.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: April 16, 2024
    Assignee: WESTLAKE PHARMACEUTICALS (HANGZHOU) CO., LTD.
    Inventors: Hongtao Yu, Qi Hu, Jing Huang, Tingliang Wang, Ningke Hou, Lijing Zhang, Wenyi Zhang, Qiaozhu Tan
  • Patent number: 11951090
    Abstract: FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (?)-epicatechin from T. cacao and showed that (?)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (?)-epicatechin for the treatment of FGFR3-related chondrodysplasias.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: April 9, 2024
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE PARIS, FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS, UNIVERSIDAD DE GRANADA
    Inventors: Laurence Legeai-Mallet, Antonio Segura Carretero, Maria De La Luz Cadiz Gurrea
  • Patent number: 11952397
    Abstract: This invention relates to crystalline forms of anhydrous Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solid forms of Compound (1), and methods of using the crystalline forms of Compound (1) and pharmaceutical compositions thereof for modulating GABA activity (e.g., positive allosteric modulation of GABA activity) and treating CNS-related disorders.
    Type: Grant
    Filed: August 2, 2023
    Date of Patent: April 9, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Shanming Kuang, Tianrui Li
  • Patent number: 11952355
    Abstract: Provided are a method of preparing a malononitrile oxime ether compound and an intermediate compound. The malononitrile oxime ether compound has a structure as shown in formula (VII), wherein W is selected from aryl or heteroaryl. The preparation method comprises: reacting a first raw material with a second raw material in the presence of a first solvent and a catalyst to obtain the intermediate compound, wherein the first raw material has a structure as shown in formula (IV), and the second raw material has a structure as shown in formula (V); and subjecting the intermediate compound, and a dehydrant to a dehydration reaction in the present of a second solvent to obtain the malononitrile oxime ether compound. Furthermore, the malononitrile oxime ether compound is obtained through one-step dehydration reaction. using the preparation method, is advantageous for improving the yield of malononitrile oxime ethers and reducing the cost.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: April 9, 2024
    Assignee: Shenyang Sinochem Agrochemicals R&D Co., Ltd.
    Inventors: Hongfei Wu, Xueming Cheng, Libao Xu, Chunxiao Guo, Jingbo Xu, Ningning Sun, Haibo Yu
  • Patent number: 11952357
    Abstract: The present disclosure relates to the field of epoxide resin, and more particularly to an epoxide with a low total chlorine content and no heavy metal residues, and a preparation method thereof. Disclosed is an epoxide prepared from raw materials including an unsaturated cycloaliphatic compound containing a double bond, hydrogen peroxide, an organic acid compound, a solvent and an alkaline salt; wherein a molar ratio of the organic acid compound to the unsaturated cycloaliphatic compound containing a double bond is (1-1.5):1. The obtained epoxides obtained in the present disclosure have a high purity, a high yield, a low solvent content, low chroma, and a low chlorine and metal ion content; the reaction system is simple, environmentally friendly, safe and controllable, and the production cost is low, which can meet the technical and economic requirements and are suitable for large-scale industrial production.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: April 9, 2024
    Assignee: JIANGSU TETRA NEW MATERIAL TECHNOLOGY CO., LTD.
    Inventors: Jianwei Han, Quan Jia, Yangjun Chang, Xiangming Cao
  • Patent number: 11952330
    Abstract: The present disclosure provides ammonium compounds, e.g., compounds according to Formula I as set forth herein, which are useful as antimicrobial agents. Methods for the treatment of bacterial infections and associated conditions, e.g., gastrointestinal conditions, are also described, as well as methods for altering the microbiome of subjects such as humans.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: April 9, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Bryan Davies, Stanton McHardy, Ashley Cunningham, Hua-Yu Wang
  • Patent number: 11945806
    Abstract: In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL patients, such as those with substantial cardiac involvement who have difficulty tolerating existing chemotherapy regimens, provided herein are small molecule compounds of Formula Ia, Formula Ib, and Formula II that are kinetic stabilizers of the native dimeric structure of full-length LCs, which compounds can slow or stop the amyloidogenicity cascade at its origin.
    Type: Grant
    Filed: March 29, 2020
    Date of Patent: April 2, 2024
    Inventors: Jeffery W. Kelly, Gareth John Morgan, Nicholas Lok Yan, Hank Michael James Petrassi
  • Patent number: 11939291
    Abstract: The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: March 26, 2024
    Assignees: University of Kansas, University of South Florida
    Inventors: Sanket Jaiprakash Mishra, Brian S. J. Blagg, Chad Anthony Dickey
  • Patent number: 11939342
    Abstract: A process for the preparation of midostaurin with high purity, particularly a process for the preparation of midostaurin with a content of oxidation impurities lower than 0.1% comprising the treatment of crude midostaurin or staurosporine with strong organic or inorganic acids in a water-immiscible solvent and, optionally, also with reducing silanes is described.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: March 26, 2024
    Assignee: PROCOS S.P.A.
    Inventors: Alberto Lena, Antonio Toppino, Katia Miele, Jacopo Roletto, Paolo Paissoni